Burning Rock Biotech Ltd.

General Information


We aim to transform precision oncology and early cancer detection. We are China’s number one NGS-based cancer therapy selection company, as evidenced by the largest market share of 26.7% in China’s NGS-based cancer therapy selection market in terms of number of patients tested in 2019, according to CIC. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.

Employees: 753
Founded: 2014
Contact Information
Address 601, 6/F, Building 3, Standard Industrial Unit 2, No.7 Luoxuan 4th Road, International Bio Island, Guangzhou, the People’s Republic of China
Phone Number +86 020-3403 7871
Web Address http://www.brbiotech.com
View Prospectus: Burning Rock Biotech Ltd.
Financial Information
Market Cap $1679.4mil
Revenues $48.7 mil (last 12 months)
Net Income $-45.0 mil (last 12 months)
IPO Profile
Symbol BNR
Exchange NASDAQ
Shares (millions): 13.5
Price range $16.50 - $16.50
Est. $ Volume $222.8 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Cowen and Company
CO-Managers CMB International/ Tiger Brokers
Expected To Trade: 6/12/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change